VBLT
Closed
Vascular Biogenics Ltd
0.168
-4.282 (-96.22%)
Last Update: 17 Oct 2023 02:58:00
Yesterday: 4.45
Day's Range: 0. - 0.
Send
sign up or login to leave a comment!
When Written:
0.1659
Vascular Biogenics Ltd (VBL) is a clinical-stage biopharmaceutical company that develops treatments for cancer and immune-inflammatory diseases. The company's lead product candidate, VB-111, is a targeted anti-cancer gene therapy that is designed to selectively destroy cancer cells by cutting off their blood supply. VB-111 is currently being studied in several clinical trials for the treatment of solid tumors, including ovarian, lung, and glioblastoma.
VBL was founded in 2000 and is headquartered in Modi'in, Israel. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "VBLT." In addition to VB-111, VBL is also developing other product candidates, including VB-601, a potential treatment for inflammatory bowel disease, and VB-511, a potential treatment for neuropathic pain.
VBL has partnerships with several pharmaceutical companies, including NanoCarrier Co. Ltd, a Japanese drug delivery company, and Biogen Inc., a global biotechnology company. The company has received funding from various sources, including grants from the Israeli government and the European Union, as well as investments from venture capital firms and institutional investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
VBL was founded in 2000 and is headquartered in Modi'in, Israel. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "VBLT." In addition to VB-111, VBL is also developing other product candidates, including VB-601, a potential treatment for inflammatory bowel disease, and VB-511, a potential treatment for neuropathic pain.
VBL has partnerships with several pharmaceutical companies, including NanoCarrier Co. Ltd, a Japanese drug delivery company, and Biogen Inc., a global biotechnology company. The company has received funding from various sources, including grants from the Israeli government and the European Union, as well as investments from venture capital firms and institutional investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!